IO Biotech Inc. (IOBT)
NASDAQ: IOBT
· Real-Time Price · USD
1.58
0.00 (0.00%)
At close: Sep 25, 2025, 3:59 PM
1.60
1.16%
After-hours: Sep 25, 2025, 05:29 PM EDT
0.00% (1D)
| Bid | 1.55 |
| Market Cap | 104.09M |
| Revenue (ttm) | 850K |
| Net Income (ttm) | -103.99M |
| EPS (ttm) | -1.58 |
| PE Ratio (ttm) | -1 |
| Forward PE | -1.67 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.64 |
| Volume | 485,887 |
| Avg. Volume (20D) | 3,294,492 |
| Open | 1.56 |
| Previous Close | 1.58 |
| Day's Range | 1.53 - 1.59 |
| 52-Week Range | 0.66 - 2.79 |
| Beta | 0.41 |
| Ex-Dividend Date | n/a |
About IOBT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IOBT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IOBT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+68.75%
IO Biotech shares are trading higher following the...
Unlock content with
Pro Subscription
1 month ago
-41.99%
Shares are trading lower after the company said its Phase 3 trial of Cylembio plus Keytruda in advanced melanoma narrowly missed the primary endpoint.
1 month ago · seekingalpha.com
IO Biotech: A Buying Opportunity Following Phase 3 Readout In MelanomaIO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should acce...
